Bax immunohistochemical expression in breast carcinoma: A study with long term follow-up

International Journal of Cancer

Volumn 79, Issue 1, 1998, Pages 13-18

  Veronese, Silvio ^a   Mauri, Francesco A ^b   Caffo, Orazio ^c   Scaioli, Monica ^b   Aldovini, Daniela ^c   Perrone, Giorgio ^b   Galligioni, Enzo ^c   Doglioni, Claudio ^d   Palma, Paolo Dalla ^c   Barbareschi, Mattia ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Ospedale SS Trinita   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d Hospital of Belluno   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; TAMOXIFEN;

ARTICLE; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR VOLUME;

BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MASTECTOMY; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032549081     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980220)79:1<13::AID-IJC3>3.0.CO;2-Z     Document Type: Article

References (22)

1. BALSLEV, I., AXELSSON, C.K., ZEDELER, K., RASMUSSEN, B.R., CARSTENSEN, B. and MOURISDEN, H.T., The Nottingham Prognostic Index applied to 9, , ,148 patients from the studies of the Danish breast cancer cooperative group (DBCG). Breast Cancer Res. Treat., 32, 281-290 (1994).
2. BARBARESCHI, M. and 13 OTHERS, Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum. Pathol., 27, 1149-1155 (1996).
3. BARGOU, R.C., DANIEL, P.T., MAPARA, M.Y., BOMMERT, K., WAGENER, C., KALLINICH, B., ROYER, H.D. and DÖRKEN, B., Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer, 60, 854-859 (1995).
4. BARGOU, R.C., WAGENER, C., BOMMERT, K., MAPARA, M.Y., DANIEL, P.T., ARNOLD, W., DIETEL, M., GUSKI, H., FELLER, A., ROYER, H.D. and DÖRKEN, B., Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. clin. Invest., 97, 2651-2659 (1996).
5. BINDER, C., MARX, D., BINDER, L., SCHAUER, A. and HIDDEMANN, W., Expression of Bax in relation to Bcl-2 and other predictive parameters in breast cancer. Ann. Oncol., 7, 129-133 (1996).
6. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long term follow-up. Clin. Cancer Res., 2, 1591-1599 (1996).
7. DOGLIONI, C., DEI TOS, A.P., LAURINO, L., CHIARELLI, C., BARBARESCHI, M. and VIALE, G., The prevalence of Bcl-2 immunoreactivity in breast carcinomas and its clincopathological correlates, with particular reference to estrogen receptor status. Virchows Arch., 424, 47-51 (1994).
8. ELSTON, C.W. and ELLIS, I.Q., Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long term follow-up. Histopathology, 19, 403-410 (1991).
9. GASPARINI, G., BARBARESCHI, M., DOGLIONI, C., DALLA PALMA, P., MAURI, F.A., BORACCHI, P., BEVILACQUA, P., CAFFO, O., MORELLI, L., PEZZELLA, F. and HARRIS, A.L., Expression of Bcl2 protein predicts efficacy of adjuvant treatment in operable breast cancer, Clin. Cancer Res., 1, 189-198 (1995).
10. HUANG, Y. RAY, S., REED, J.C., IBRADO, A.M., TANG, C., NAWABI, A. and BHALLA, K., Estrogen increases intracellular p26Bcl-2 to p21 Bax ratios and inhibits taxol-induced apoptosis of human breast cancer MCF-7 cells. Breast Cancer Res. Treat., 42, 73-81 (1997).
11. KAPUCUOGLU, N., LOSI, L. and EUSEBI, V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive breast carcinomas. Virchows Arch., 430, 17-22 (1997).
12. KRAJEWSKI, S., BLOMQVIST, C., FRANSSILA, K., KRAJEWSKA, M., WASENIUS, V.M., NISKANEN, E. and REEP, J.C., Reduced expression of the proapoptotic gene BAX is associated with poor response rates to combined chemotherapy and shortened survival in women with metastatic breast adenocarcinoma. Cancer Res., 55, 4471-4478 (1995).
13. KRAJEWSKI, S., KRAJEWSKA, M., SHABAIK, A., MIYASHITA, T., WANG, H.G. and REED, J.C., Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Amer. J. Pathol., 145, 1323-1336 (1994).
14. MIYASHITA, T., KITADA, S., KRAJEWSKI, S., HORNE, W.A., DELIA, D. and REED, J.C., Overexpression of the Bcl-2 protein increases the half-life of p21 (Bax). J. biol. Chem., 270, 26049-26052 (1995).
15. MIYASHITA, T. and REED, J.C., Tumor suppressor p53 is a direct transcriptional activator of the human to: gene. Cell, 80, 293-299 (1995).
16. OGRETMEN, B. and SAFA, A.R., Down-regulation of apoptosis-related bcl-2 but not bcl-x(L) or bax proteins in multidrug-resistant MCF-7/Adr human breast cancer cells. Int. J. Cancer, 67, 608-614 (1996).
17. OLTVAI, Z.N. and KORSMEYER, S.J., Checkpoints of dueling dimers foil death wishes. Cell, 79, 189-192 (1994).
18. PEREGO, P., GIAROLA, M., RIGHETTI, S.C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M.A., MIYASHITA, T., REED, J.C. and ZUNINO, F., Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
19. PIETENPOL, J.A., PAPADOPOULOS, N., MARKOWITZ, S., WILLSON, J.K.W., KINZLER, K.W. and VOGELSTEIN, B., Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res., 54, 3714-3717 (1994).
20. SAKAKURA, C. and 14 OTHERS, Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer, 67, 101-105(1996).
21. STROBEL, T., SWANSON, L., KORSMEYER, S. and CANNISTRA, S.A., BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc. nat. Acad. Sci. (Wash.), 93, 14094-14099 (1996).
22. YIN, C.Y., KNUDSON, C.M., KORSMEYER, S.J. and VANDYKE, T., Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature (Lond.), 385, 637-640 (1997).